Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6848815 | 1.00 | TSHR (0.41) | TSHRAPPBRD4PDK2 | |
| Hydrochloric Acid SCHEMBL6846381 | 0.98 | TSHR (0.39) | TSHRAPPBRD4 | |
| Hydrochloric Acid SCHEMBL6841993 | 0.98 | TSHR (0.39) | TSHRAPPBRD4 | |
| SCHEMBL26274192 | 0.85 | TSHR (0.42) | TSHRAPPBRD4 | |
| SCHEMBL20048797 | 0.82 | TSHR (0.39) | TSHRAPPBRD4 | |
| SCHEMBL21691165 | 0.82 | TSHR (0.39) | TSHRAPPBRD4 | |
| SCHEMBL20048796 | 0.82 | TSHR (0.39) | TSHRAPPBRD4 | |
| Hydrochloric Acid SCHEMBL27480555 | 0.80 | MAPT (0.35) | — | |
| SCHEMBL12403875 | 0.79 | — | — | |
| SCHEMBL4100234 | 0.74 | CYP1A2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170260174-A1 | Benzene, Pyridine, and Pyridazine Derivatives | ESANEX INC (US) | 2017-09-14 | — | — | US | disclosed |
| US-9656956-B2 | Benzene, pyridine, and pyridazine derivatives | ESANEX, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20140343037-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | SERENEX, INC. | 2014-11-20 | — | — | US | disclosed |
| US-8309548-B2 | Benzene, pyridine, and pyridazine derivatives | SERENEX, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20110183977-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | SERENEX, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| US-7906529-B2 | Benzene, pyridine, and pyridazine derivatives | SERENEX, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-6774263-B1 | N-(2-CHLORO-5-METHYLTHIOPHENYL)-N'-(3-METHYLSULFINYLPHENYL)-N' -METHYLGUANIDINE; NEURODEGENERATIVE DISORDER TREATMENT | CAMBRIDGE NEUROSCIENCE, INC. | 2004-08-10 | — | — | US | disclosed |
| EP-0705100-B1 | THERAPEUTIC SUBSTITUTED GUANIDINES | CENES LTD (GB) | 2003-07-30 | — | — | EP | disclosed |
| EP-1041986-A4 | PHARMACEUTICALLY ACTIVE COMPOUND AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE INC (US) | 2001-03-21 | — | — | EP | disclosed |
| US-6156741-A | Therapeutic substituted guanidines | CAMBRIDGE NEUROSCIENCE, INC. (US) | 2000-12-05 | — | — | US | disclosed |
| US-6153604-A | Therapeutic substituted guanidines | CAMBRIDGE NEUROSCIENCE, INC. (US) | 2000-11-28 | — | — | US | disclosed |
| US-6147063-A | NEUROTOXICITY | CAMBRIDGE NEUROSCIENCE, INC. (US) | 2000-11-14 | — | — | US | disclosed |
| EP-1041986-A1 | PHARMACEUTICALLY ACTIVE COMPOUND AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999018962-A1 | PHARMACEUTICALLY ACTIVE COMPOUND AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-04-22 | — | — | WO | disclosed |
| EP-0705100-A4 | THERAPEUTIC SUBSTITUTED GUANIDINES | CAMBRIDGE NEUROSCIENCE INC (US) | 1996-05-29 | — | — | EP | disclosed |
| EP-0705100-A1 | THERAPEUTIC SUBSTITUTED GUANIDINES | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1996-04-10 | — | — | EP | disclosed |
| WO-1994027591-A1 | THERAPEUTIC SUBSTITUTED GUANIDINES | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260174-A1 | Benzene, Pyridine, and Pyridazine Derivatives | CDK4, P2RX4, MKI67 | TSHR 1413/4885APP 2582/4885BRD4 5/4885 |
| US-20140343037-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | CDK4, P2RX4, MKI67 | TSHR 1413/4885APP 2582/4885BRD4 5/4885 |
| US-20110183977-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | CDK4, P2RX4, MKI67 | TSHR 1413/4885APP 2582/4885BRD4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.